The US FDA has approved Mesoblast's Ryoncil (remestemcel-L-rknd) for treating steroid-refractory acute graft-versus-host disease (SR-aGVHD) in pediatric patients 2 months and older. …
FDA approves Mesoblast's cell therapy to treat steroid-refractory acute graft-versus-host disease
December 19, 2024 Australian Biotech
Latest Video
New Stories
-
The 'Week in Review' - 24 January
January 24, 2025 - - Podcast -
Cabinet documents reveal decades-old focus on faster PBS listings
January 24, 2025 - - Latest News -
No probity advisor but what about a form of confidentiality deed?
January 24, 2025 - - Latest News -
CEPI backing for Vaxxas to advance needle-free thermostable mRNA vaccines
January 23, 2025 - - Latest News -
New preventive treatments could support ongoing fight against COVID
January 23, 2025 - - Latest News -
Pharmac encourages input on on multiple medicines funding proposal
January 22, 2025 - - Latest News -
Immutep completes patient enrolment for EFTISARC-NEO Phase 2 trial
January 22, 2025 - - Australian Biotech